Panion begins gene therapy safety study in dogs
Swedish firm Panion Animal Health has started a safety study for its canine gene therapy candidate at the University of Copenhagen in Denmark.
Panion is developing the treatment for dogs with drug-resistant epilepsy. The company is moving its R&D work into the clinical stage and the findings will supplement safety data from a previous dog study "that was very encouraging".
The new study will be led by associate professor David Woldbye, who Panion said is an expert in development of gene therapy for treatment of epilepsy.
Panion also recently gained positive results in an efficacy study of its gene therapy candidate – CG01 canine. Panion has a license agreement for dogs and cats with its parent company CombiGene, which is developing a gene therapy approach for the treatment of human epilepsy. CombiGene's work was originally based on discoveries made at the University of Copenhagen and Sweden's Lund University.